PDT Partners’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-23,654
| Closed | -$273K | – | 767 |
|
|
2025
Q1 | $273K | Sell |
23,654
-11,547
| -33% | -$133K | 0.02% | 628 |
|
|
2024
Q4 | $298K | Buy |
35,201
+12,747
| +57% | +$108K | 0.03% | 582 |
|
|
2024
Q3 | $260K | Buy |
+22,454
| New | +$260K | 0.02% | 624 |
|
|
2024
Q2 | – | Sell |
-41,951
| Closed | -$498K | – | 706 |
|
|
2024
Q1 | $498K | Buy |
+41,951
| New | +$498K | 0.05% | 453 |
|
|
2023
Q4 | – | Sell |
-37,754
| Closed | -$364K | – | 606 |
|
|
2023
Q3 | $364K | Buy |
37,754
+448
| +1% | +$4.31K | 0.05% | 451 |
|
|
2023
Q2 | $336K | Sell |
37,306
-35
| -0.1% | -$315 | 0.05% | 441 |
|
|
2023
Q1 | $294K | Sell |
37,341
-9,703
| -21% | -$76.3K | 0.04% | 465 |
|
|
2022
Q4 | $318K | Buy |
+47,044
| New | +$318K | 0.05% | 474 |
|
|
2022
Q3 | – | Sell |
-14,113
| Closed | -$139K | – | 960 |
|
|
2022
Q2 | $139K | Buy |
+14,113
| New | +$139K | 0.01% | 864 |
|
|
2020
Q3 | – | Sell |
-16,325
| Closed | -$198K | – | 790 |
|
|
2020
Q2 | $198K | Sell |
16,325
-2,975
| -15% | -$36.1K | 0.01% | 595 |
|
|
2020
Q1 | $148K | Sell |
19,300
-4,652
| -19% | -$35.7K | 0.01% | 586 |
|
|
2019
Q4 | $427K | Buy |
+23,952
| New | +$427K | 0.03% | 452 |
|